Beyond Antibiotics: Lakewood-Amedex Advances Diabetic Foot Ulcer Trial
Lakewood-Amedex Biotherapeutics doses its first Phase 2a patient with Nu-3 Gel for mildly infected diabetic foot ulcers and drug resistance.
Stocks · News reference
Market-Moving News for September 1st
LABT: 43% | Lakewood-Amedex Biotherapeutics shares are trading higher after the company received a notice of allowance for a U.S. patent titled "ANTIMICROBIAL COMPOUNDS, COMPOSITIONS, AND USES THEREOF" PXS: 23%
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
Lakewood-Amedex Biotherapeutics Announces First Patient Dosed In Phase 2a Trial Of Nu-3 For Infected Diabetic Foot Ulcers; Topline Data Expected In Q1 2027
Lakewood-Amedex Biotherapeutics CEO Issues Shareholder Letter to Shareholders
To our shareholders,The second quarter of 2026 represented a transformational period in the evolution of Lakewood-Amedex Biotherapeutics. We successfully transitioned to a Nasdaq-listed public company, significantly
Lakewood-Amedex Registers Resale Of Up To 4,512,400 Shares Of Common Stock By Selling Stockholder
LAKEWOOD-AMEDEX BIOTHERAPEUTICS INC. 4,512,400 Shares of Common Stock This prospectus relates to the resale from time to time of up to 4,512,400 shares of common stock, par value $0.0001 per share, of Lakewood-Amedex
Cardiorespiratory Assessment Units Market Poised for Growth Through 2035 as Advanced Technologies and Expanding Clinical Applications Create New Opportunities
The global Cardiorespiratory Assessment Units Market is projected to grow from USD 1.48 billion in 2025 to USD 2.98 billion by 2035, expanding at a CAGR of 7.23%. Growth is driven by rising prevalence of COPD and heart failure, innovation in portable AI-enabled systems, and expanding remote care applications. However, high equipment costs and staffing requirements remain challenges. North America leads with 35.12% market share.
Mexico Cardiac Rhythm Management Devices Market Outlook to 2036 Provides Revenue, Volume, Pricing and Competitive Insig
ResearchAndMarkets.com released a comprehensive market report on Mexico's cardiac rhythm management devices sector, covering CRT, ICDs, and pacemakers through 2036. The report provides revenue forecasts, sales volume data, pricing analysis, and 2025 competitive positioning for major market players, supporting strategic decision-making for manufacturers, investors, and healthcare stakeholders.